Source: Annual Congress 2012 - Pulmonary circulation: end-points and biomarkers
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Skoro-Sajer, G. Hlavin, S. Aschauer, M. Wolzt, I. Lang (Austria). Asymmetric dimethylarginine, a biomarker for the effects of drug therapy in pulmonary hypertension. Eur Respir J 2012; 40: Suppl. 56, 2831

Member's Comments

No comment yet.

Related content which might interest you: Asymmetric dimethylarginine (ADMA) to monitor treatments of pulmonary hypertension Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Biomarkers in pulmonary hypertension Source: Eur Respir J 2008; 32: 503-512 Year: 2008 The association between pulmonary arterial hypertension secondary to chronic lung disease and serum asymmetric dimethylarginine levels Source: Annual Congress 2012 - COPD comorbidities II Year: 2012 Attenuated expression and activity of dimethylarginine dimethylaminohydrolase may play a key role in monocrotaline-induced pulmonary hypertension by accumulation of endogenous NOS inhibitors in rats Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 The role of asymmetric dimethylarginine (ADMA) in patients with asthma Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Asymmetric dimethylarginine and asthma Source: Eur Respir J 2014; 43: 647-648 Year: 2013 Metabolic dysfunction associated with redox imbalance in pulmonary hypertension: Effects of the prolonged sildenafil use Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Pulmonary hypertension: future therapies Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=84 Year: 2004 Circulating endothelial cell levels decrease after vasodilator therapy and are a biomarker of clinical worsening in refractory pulmonary hypertension in children Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Ventilation-perfusion relationships in severe pulmonary hypertension. Effects of acute and long-term treatment with prostacyclin Source: Eur Respir J 2001; 18: Suppl. 33, 253s Year: 2001 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009 Inhaled iloprost did not influence cytokines levels in patients with different forms of pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Impact of therapies on insulin resistance in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010 Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2) Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017 Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 57 (4) 2003201; 10.1183/13993003.03201-2020 Year: 2021 Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004